Membranous glomerulonephritis: a modern view of the problem and treatment options


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review presents the main mechanisms of development and treatment of membranous glomerulonephritis (GLN) with an emphasis on the primary (idiopathic) form. The leading role of anti-PLA2R antibodies in the development of primary membranous gln has been shown. some genetic aspects of the occurrence of primary membranous gln are considered. The development factors and pathogenetic mechanisms of secondary membranous gln are described. The main provisions in the treatment of the primary form of membranous gln are considered.

Full Text

Restricted Access

About the authors

Ilkhom T. Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy; Kyrgyz Russian Slavic University

Email: murkamilov.i@mail.ru
PhD in Medical Sciences, Nephrologist, Deputy Associate Professor at the Department of Faculty Therapy Bishkek, Kyrgyzstan

Ibragim S. Sabirov

Kyrgyz Russian Slavic University

Email: sabirov_is@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Therapy № 2 in the specialty “General Medicine” Bishkek, Kyrgyzstan

Victor V. Fomin

I.M. Sechenov First Moscow State Medical University

Email: fomin_vic@mail.ru
Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Vice-Rector for Clinical Work and Postgraduate Professional Education, Director of the V.N. Vinogradov Faculty Therapy Clinic, Head of the Faculty Therapy Department № 1 Moscow

Zh. A Murkamilova

Kyrgyz Russian Slavic University

Email: murkamilovazh.t@mail.ru
Nephrologist, Correspondence Postgraduate Student at the Department of Therapy № 2 in the specialty “General Medicine” Bishkek, Kyrgyzstan

Kuvanych A. Aitbaev

Research Institute of Molecular Biology and Medicine

Email: kaitbaev@yahoo.com
Doctor of Medical Sciences, Professor, Head of the Laboratory of Pathological Physiology Bishkek, Kyrgyzstan

References

  1. Бобкова И.Н., Козловская Л.В., Цыгин А.Н., Шилов Е.М. Клинические рекомендации по диагностике и лечению мембранозной нефропатии. Нефрология. 2014;18(4) :93-100
  2. Floege J., Barbour S.J., Cattran D.C., et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95:268-280. doi: 10.1016/j.kint.2018.10.018.
  3. Бобкова И.Н., Кахсуруева П.А., Ставровская Е.В., Филатова Е.Е. Эволюция в понимании патогенеза идиопатической мембранозной нефропатии: от экспериментальных моделей к клинике. Альманах клинической медицины. 2017;45(7):553-564. Doi: https://doi.org/10.18786/2072-0505-2017-45-7-553-564
  4. Бобкова И.Н., Кахсуруева П.А., Ставровская Е.В. Идиопатическая мембранозная нефропатия: эволюция в понимании проблемы. Тер. архив.2016;6:89-94. doi: 10.17116/terarkh201688689-94
  5. Polanco N, Gutierrez E., Covarsi A., et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2010;21(4):697-704. doi: 10.1681/ASN.2009080861.
  6. Камышова Е.С., Бобкова И.Н., Горелова И.А. и др. Генетические детерминанты развития и течения мембранозной нефропатии. Тер. архив. 2018;6(90):105-111. Doi: https://doi.org/10.26442/terarkh2018906105-11.
  7. Добронравов В.А., Лапин С.В., Лазарева Н.М. и др. Циркулирующие антитела к рецептору фосфолипазы А2 при первичной мембранозной нефропатии. Нефрология. 2012;16(4):39-44. Doi: https://doi.org/10.24884/1561-6274-2012-16-4-39-44
  8. Cravedi P., Jarque M., Angeletti A., et al. Immune-monitoring disease activity in Primary Membranous Nephropathy. Frontiers in Medicine.2019;6:241. doi: 10.3389/fmed.2019.00241.
  9. An C., Akankwasa G, Liu J., et al. Urine markers of renal tubular injury in idiopathic membranous nephropathy: a cross sectional study. Clin. Chim. Acta. 2019;492:7-11. doi: 10.1016/j.cca.2019.01.015.
  10. Huh H., Lee H., Lee J.P, et al. Factors affecting the long-term outcomes of idiopathic membranous nephropathy. BMC Nephrol. 2017;18:104. doi: 10.1186/s12882-017-0525-6.
  11. Liu W, Gao C., Dai H., et al. Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role. Front. Immunol. 2019;10:1809. Published 2019 Aug 6. doi: 10.3389/fimmu.2019.01809.
  12. Bomback A.S., Fervenza F.C. Membranous nephropathy: approaches to treatment. Am. J. Nephrol. 2018;47:1:30-42. Doi: https://doi. org/10.1159/000481635
  13. Добронравов В.А., Майер Д.А., Бережная О.В. и др. Мембранозная нефропатия в российской популяции. Тер. архив. 2017;6(89):21-29. Doi: 10.17116/ terarkh201789621-29. [Dobronravov V.A., Mayer D.A., Berezhnaya O.V., et al. Membranous nephropathy in a Russian population. Therapeutic Archive.2017;6(89):21-29. doi: 10.17116/terarkh201789621-29. (in Russ.)].
  14. Hayashi N., Okada K., Matsui Y., et al. Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy. Nephrol. Dial. Transplant. 2018;33:832-40. doi: 10.1093/ndt/gfx235.
  15. Luo W., Olaru F., Miner J.H., et al. Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy. Front. Immunol. 2018;9:1433. Doi: 10.3389/ fimmu.2018.01433.
  16. Beck L.H., Bonegio R.G., Lambeau G., et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 2009;361:11-21. doi: 10.1056/NEJMc1011678.
  17. Debiec H., Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N. Engl. J. Med. 2011;364:689-690. Doi: 10.1056/ NEJMc1011678.
  18. Hofstra J.M., Beck L.H., Beck D.M., et al. Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2011;6(6):1286-1291. Doi: 10.2215/ CJN.07210810.
  19. Stahl R., Hoxha E., Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N. Engl. J. Med. 2010;363(5):496-498. doi: 10.1056/NEJMC1003066.
  20. Бобылева И.А., Кахсуруева П.А., Камышова Е.С. и др. Клиникогенетические особенности идиопатической мембранозной нефропатии у российских пациентов. Клин. нефрология. 2019;3(11):31-36. doi: 10.18565/nephrology.2019.3.31-36.
  21. Liu Y.H., Chen C.H., Chen S.Y., et al. Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan. J. Biomed. Sci. 2010;17:18. Doi: https://doi.org/10.1186/1423-0127-17-81.
  22. Cui Z., Xie L.J, Chen F.J., et al. MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2017;28(5):1651-1664. doi: 10.1681/ASN. 2016020114.
  23. Le W.B., Shi J.S., Zhang T., et al. HLA-DRB1*15:01 and HLADRB3*02:02 in PLA2R-related membranous nephropathy. J. Am. Soc. Nephrol. 20(7;28(5):1642-1650.Doi: 10.1681/ ASN.2016060644.
  24. Gupta S., Kottgen A., Hoxha E., et al. Genetics of membranous nephropathy. Nephrol. Dial. Transplant. 2018;33:9:1493-1502. doi: 10.1093/ndt/gfX296.
  25. Stanescu H.C., Arc os-Burgos M., Medlar A., et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N. Engl. J. Med. 2011;364:616-626. doi: 10.1056/NEJMoa1009742.
  26. Hoxha E., Beck L.H.Jr., Wiech T., et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J. Am. Soc. Nephrol. 2017;28:520-531. doi: 10.1681/ASN.2016010050.
  27. Hoxha E., Wiech T., Stahl P.R., et al. A mechanism for cancer-associated membranous nephropathy. N. Engl. J. Med. 2016;374:1995-1996. doi: 10.1056/NEJMc1511702.
  28. Beck L.H.Jr. PLA2R and THSD7A: disparate paths to the same disease? J. Am. Soc. Nephrol. 2017;28:2579-2589. doi: 10.1681/ASN.2017020178.
  29. Tomas N.M., Beck L., Meyer-Schwesinger C., et al. Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. N. Engl. J. Med. 2014;371(24):2277-2287. doi: 10.1056/NEJMc1011678.
  30. Tomas N.M., Meyer-Schwesinger C., von Spiegel H., et al. A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. J. Am. Soc. Nephrol. 2017;28:3262-3277. Doi: 10.1681/ ASN.2017010030.
  31. Larsen C.P., Cossey N., Beck L.H. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Modern. Pathol. 2016;100:1-6. doi: 10.1038/modpathol.2016.
  32. Neale T.J., Ojha P.P., Exner M., et al. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IVcollagen. J. Clin. Invest. 1994;94:1577-1584. doi: 10.1172/jci117499.
  33. Prunotto M., Carnevali M.L., Candiano G., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. JASN. 2010;21:507-519. doi: 10.1681/asn.2008121259.
  34. Pozdzik A., Brocheriou I., David C., et al. Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management. BioMed Res. Int. 2018.2018. Doi: https://doi. org/10.1155/2018/6281054.
  35. Buelli S., Perico L., Galbusera M., et al. Mitochondrial-dependent autoimmunity in membranous nephropathy of IgG4-related disease. EBioMedicine. 2015;2(5):456-466. Doi: https://doi.org/10.1016/j.ebiom.2015.03.003.
  36. Couser W.G. Primary membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2017;12:983-997. doi: 10.2215/CJN.11761116.
  37. Смирнов А.В., Наточин Ю.В. Нефрология: фундаментальная и клиническая. Нефрология. 2019;23(4):9-26. Doi: https://doi.org/10.24884/1561-6274-2019-23-4-9-26.
  38. Penny M.J., Boyd R.A., Hall B.M. Permanent CD8-Tcell depletion prevents proteinuria in active Heymann nephritis. J. Exp. Med. 1998;188:1775-1784. doi: 10.1084/jem.188.10.1775.
  39. Dahan K., Debiec H., Plaisier E., et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J. Am. Soc. Nephrol. 2017;28(1):348-358. Doi: https://doi.org/10.1681/ASN.2016040449.
  40. Fervenza F.C., Appel G.B., Barbour S.J., et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 2019;381:36-46. doi: 10.1056/NEJMoa1814427.
  41. Couser W.G, Johnson R.J. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int. 2014;86(5):905-914. Doi: https://doi.org/10.1038/ki.2014.49.
  42. Dimitriades C., Shetty A.K., Vehaskari M., et al. Membranous nephropathy associated with childhood sarcoidosis. Pediatr. Nephrol. 1999;13(5):444-447. Doi: https://doi.org/10.1007/s004670050637
  43. Rovin B.H., Caster D.J., Cattran D.C., et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):281-295. Doi: https://doi.org/10.1016/j.kint.2018.11.008
  44. Beauvais P., Vaudour G., Gibod L.B., Levy M. Membranous nephropathy associated with ovarian tumour in a young girl: recovery after removal. Eur. J. Pediatr. 1989;148(7):624-625. Doi: https://doi.org/10.1007/BF00441515.
  45. Ronco P.M. Nephrology Forum: Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56(1):355-77. Doi: https://doi. org/10.1046/j.1523-1755.1999.00548.x
  46. Ryu J., Ryu H., Kim S., et al. Comparison of cancer prevalence between patients with glomerulonephritis and the general population at the time of kidney biopsy. PloS one. 2019; 14:10. Doi: https://doi.org/10.1371/journal. pone.0224024
  47. Takova N., Otsetov A. Nephrotic Sydrome Can Be a Marker for Prostatic Carcinoma. Mod. Res. Inflammat.2017;6:29-36. Doi: 10.4236/ mri.2017.64004.
  48. de Francisco A.L., Maci'a M., Alonso F., et al. Onco-Nephrology: Cancer, chemotherapy and kidney. Nefrol. (English Edition). 2019;39(5):473-481. Doi: https://doi.org/10.1016/j.nefroe.2018.10.016
  49. Аниконова Л.И., Ряснянский В.Ю., Макарьева Е.Ю., Воробьева О.А. Фокально-сегментарный гломерулосклероз, ассоциированный с хроническим лимфолейкозом: клинический случай и литературный обзор. Нефрология. 2016;20(6): 101-110.
  50. Moulin B., Ronco PM., Mougenot B., et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphoma. Kidney Int. 1992;42(1):127-135. Doi: https://doi.org/10.1038/ki.1992.270
  51. Sethi S., Madden B.J., Debiec H., et al. Exostosin 1/exostosin 2-associated membranous nephropathy. J. Am. Soc. Nephrol. 2019;30:1123-1136. doi: 10.1681/ASN.2018080852.
  52. Ahmad S.B., Appel G.B. Antigens, antibodies, and membranous nephropathy: a decade of progress.Kidney Int. 2020;97(1):29-31. Doi: https://doi. org/10.1016/j.kint.2019.10.009
  53. Bobart S.A., De Vriese A.S., Pawar A.S, et al. Non-invasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-438. doi: 10.1016/j.kint.2018.10.021.
  54. Chen C.H., Wu H.Y., Wang C.L., et al. Proteinuria as a therapeutic target in advanced chronic kidney disease: a retrospective multicenter cohort study. Sci. Rep. 2016;6:26539. doi: 10.1038/srep26539.
  55. Смирнов А.В. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология. 2010;14(4):9-22. Doi: h ttps://doi.юг/15.1462441561-62 44-29114-4-9-22
  56. Rossi P., Demoux A.L., Granel B., et al. Anti-CD20 monoclonal antibody or treatment of refractory autoimmune haemolytic anemia associated with idiopathic membranous nephropathy. Rheumatol. (Oxford). 2005;44(3):403-405. Doi: https://doi.org/10.1093/rheumatology/keh463
  57. Малышева С.А., Борисов А.Г., Романов В.П., Потехин Н.П. Терапия ритуксимабом первичной мембранозной нефропатии, резистентной к иммуносупрессивной терапии (клиническое наблюдение). Нефрология и диализ.2014;3(16):382-385.
  58. Томилина Н.А., Бирюкова Л.С., Фролова Н.Ф., Столяревич Е.С. Применение ритуксимаба при лечении мембранозной нефропатии (опыт одного центра). Нефрология и диализ. 2019;4(21):489-490

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies